Encouraging results from three pipeline combination therapies suggests Vertex could extend treatment to patients with more severe and difficult to treat cystic fibrosis.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
